Literature DB >> 8149612

Effect of serum lipoprotein(a) on estimation of low-density lipoprotein cholesterol by the Friedewald formula.

K M Li1, D E Wilcken, N P Dudman.   

Abstract

The calculation of serum low-density lipoprotein cholesterol (LDL-C) by the Friedewald formula does not account for the cholesterol associated with lipoprotein(a) [Lp(a)]. To quantify the contribution of Lp(a) cholesterol to total serum cholesterol, we measured concentrations of serum Lp(a) by an ELISA and concentrations of other serum lipids and lipoproteins by standard assays in 23 normolipemic women, ages 50-60 years. In measuring serum high-density lipoprotein we found that polyethylene glycol 6000 precipitated > 99.8% of all Lp(a). When serum Lp(a) concentrations were < or = 300 mg/L, 301-600 mg/L, and > 600 mg/L, the uncorrected serum LDL-C was overestimated, respectively, by a mean of 4.1% (n = 7), 8.5% (n = 8), and 21.4% (n = 8). Serum Lp(a) concentrations were positively correlated with percentage overestimation (P < 0.001), but were not correlated with either corrected or uncorrected serum LDL-C. We conclude that the Friedewald formula should be modified to take into account the contribution of Lp(a) cholesterol to total serum cholesterol.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8149612

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  16 in total

Review 1.  Genetics of lipid traits and relationship to coronary artery disease.

Authors:  Tanya E Keenan; Daniel J Rader
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

Review 2.  ACP Broad Sheet no 151: September 1997. Investigation of dyslipidaemias.

Authors:  A F Winder; W Richmond; D T Vallance
Journal:  J Clin Pathol       Date:  1997-09       Impact factor: 3.411

3.  L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.

Authors:  M Florentin; M S Elisaf; C V Rizos; V Nikolaou; E Bilianou; C Pitsavos; E N Liberopoulos
Journal:  Lipids       Date:  2016-12-02       Impact factor: 1.880

4.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

5.  Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia.

Authors:  E Meriño-Ibarra; J Puzo; E Jarauta; A Cenarro; D Recalde; A L García-Otín; E Ros; E Martorell; X Pintó; M Franco; D Zambón; A Brea; M Pocoví; F Civeira
Journal:  J Inherit Metab Dis       Date:  2007-10-20       Impact factor: 4.982

6.  New modified Friedewald formulae for estimating low-density lipoprotein cholesterol according to triglyceride levels: extraction and validation.

Authors:  Asghar Ghasemi; Samaneh Asgari; Farzad Hadaegh; Masoumeh Kheirandish; Iraj Azimzadeh; Fereidoun Azizi; Maryam Tohidi
Journal:  Endocrine       Date:  2018-07-24       Impact factor: 3.633

7.  Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).

Authors:  Harshal A Deshmukh; Helen M Colhoun; Toby Johnson; Paul M McKeigue; D John Betteridge; Paul N Durrington; John H Fuller; Shona Livingstone; Valentine Charlton-Menys; Andrew Neil; Neil Poulter; Peter Sever; Denis C Shields; Alice V Stanton; Aurobindo Chatterjee; Craig Hyde; Roberto A Calle; David A DeMicco; Stella Trompet; Iris Postmus; Ian Ford; J Wouter Jukema; Mark Caulfield; Graham A Hitman
Journal:  J Lipid Res       Date:  2012-02-24       Impact factor: 5.922

8.  Silent coronary artery disease in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a) polymorphism.

Authors:  Carmine Gazzaruso; Adriana Garzaniti; Stefano Giordanetti; Colomba Falcone; Pietro Fratino
Journal:  Cardiovasc Diabetol       Date:  2002-11-22       Impact factor: 9.951

9.  Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS).

Authors:  Mehdi Afshar; Louise Pilote; Line Dufresne; James C Engert; George Thanassoulis
Journal:  J Am Heart Assoc       Date:  2016-04-23       Impact factor: 5.501

10.  Variations of lipoprotein(a) levels in the metabolic syndrome: a report from the Maracaibo City Metabolic Syndrome Prevalence Study.

Authors:  Valmore Bermúdez; Joselyn Rojas; Juan Salazar; Luis Bello; Roberto Añez; Alexandra Toledo; Maricarmen Chacín; Miguel Aguirre; Marjorie Villalobos; Mervin Chávez; María Sofía Martínez; Wheeler Torres; Yaquelin Torres; José Mejías; Edgardo Mengual; Liliana Rojas; Milagro Sánchez de Rosales; Ana Quevedo; Raquel Cano; Mayela Cabrera; Rafael París; Adonías Lubo; María Montiel; Climaco Cano
Journal:  J Diabetes Res       Date:  2013-04-22       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.